Sanofi halts riliprubart MOBILIZE phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy

Clinical Trial Outcomes

Hesperos establishes strategic sales partnership with AsedaSciences to augment compound safety prediction

Intra-industry partnerships

Hesperos awarded Phase IIB SBIR grant to investigate drug-induced cognitive impairment using its Human-on-a-Chip®

Grants Awarded & Funds Raised

Hesperos' chronic inflammatory demyelinating polyneuropathy-on-chip instrumental to achieving orphan drug designation

Clinical Trial Authorizations